BMC
Gastroenterology

RESEARCH ARTICLE   **Open Access**

hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions

Tanielly Cristina Raiol Silva[1†], Mariana Ferreira Leal[2*†], Danielle Queiroz Calcagno[2],
Carolina Rosal Teixeira de Souza[1], André Salim Khayat[1], Ney Pereira Carneiro dos Santos[3],
Raquel Carvalho Montenegro[1], Silvia Helena Barem Rabenhorst[4], Mayara Quaresma Nascimento[1],
Paulo Pimentel Assumpção[3], Marília de Arruda Cardoso Smith[2] and Rommel Rodríguez Burbano[1]

Abstract

Background: Gastric cancer is a serious public health problem in Northern Brazil and in the world due to its high incidence and mortality. Despite the severity of the disease, more research is needed to better understand the molecular events involved in this intestinal-type gastric carcinogenesis process. Since precancerous lesions precede intestinal-type gastric cancer, here, we evaluated the *hTERT*, *MYC*, and *TP53* mRNA and protein expression, as well as *TP33* copy number, in gastric preneoplastic lesions.

Methods: We evaluated 19 superficial gastritis, 18 atrophic gastritis, and 18 intestinal metaplasia from cancer-free individuals of Northern Brazil. Quantitative reverse transcription PCR was used to analyze the mRNA expression and immunohistochemical methods were used to assess protein immunoreactivity in tissue samples. The number of *TP53* gene copies was investigated in gastric diseases by quantitative PCR.

Results: We observed hTERT, MYC, and p53 immunoreactivity only in intestinal metaplasia samples. The immunoreactivity of these proteins was strongly associated with each other. A significantly higher MYC mRNA expression was observed in intestinal metaplasia compared to gastritis samples. Loss of *TP53* was also only detected in intestinal metaplasia specimens.

Conclusions: We demonstrated that hTERT, MYC, and TP53 are deregulated in intestinal metaplasia of individuals from Northern Brazil and these alterations may facilitate tumor initiation.

Keywords: hTERT, MYC, TP53, Gastric carcinogenesis, Precancerous lesions

Background

Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1]. In Northern Brazil, gastric cancer is the second most frequent neoplasia among males and the third in females [2]. Some histopathological lesions precede well-differentiated or intestinal-type gastric cancer. These neoplasia types progress through a number of sequential steps beginning with superficial gastritis, followed by chronic atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia, and finally, carcinoma [3]. Although

this neoplasia is a serious public health problem in Northern Brazil and in the world, little is known about the molecular events involved in the gastric carcinogenesis process. A better understanding of the critical alterations implicated in tumor initiation is necessary to reduce the mortality rates through early diagnosis and treatment.

Cell immortalization has been reported as an important event in carcinogenesis. This process requires activation of telomerase, an enzyme essential for stabilizing telomere length. Telomerase activation is described in about 90% of human cancers, while most normal tissues contain inactivated telomerase [4]. In the absence of genome checkpoint functions, telomere dysfunction accelerates genomic instability, facilitating tumor initiation [5]. This genomic instability caused by telomere dysfunction

* Correspondence: mariana.morf@epm.br
†Equal contributors
2Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, Rua Botucatu 740, CEP 04023-900, São Paulo, SP, Brazil
Full list of author information is available at the end of the article

occurs in the early stages of carcinogenesis, before telomerase activation. Subsequently, telomeres in these initiated cells undergo further progressive shortening, generating rampant chromosomal instability and threatening cell survival. Telomerase activation occurs at this stage to stabilize the genome and confer unlimited proliferative capacity upon the emerging and evolving cancer cell. Therefore, cells that have acquired telomerase activity can obtain the capacity for cancer progression [6].

Transcriptional regulation of *hTERT* (the catalytic subunit of telomerase) gene is the major mechanism for cancer-specific activation of telomerase. Several factors have been reported to directly or indirectly regulate the *hTERT* promoter, including cellular transcriptional activators, such as MYC, as well as the repressors, such as p53 (see review [6]).

The *MYC* proto-oncogene has been described as a key in the gastric carcinogenic process [7]. MYC protein has an effect on about 15% of genes in the human genome [8]. MYC activates several genes involved in cell cycle regulation, metabolism, ribosome biogenesis, protein synthesis, and mitochondrial function, while it consistently represses genes involved in cell growth arrest and cell adhesion, and also has a direct role in the control of DNA replication [9]. Among the *MYC* target genes are *hTERT* as well as *TP53* [9].

TP53 is a key tumor suppressor gene in the carcinogenesis process [10] acting in the DNA damage response and apoptosis, as well as a regulator of cell metabolism [11]. *TP53* somatic alteration is described in approximately 50% of human cancers, including gastric cancer [10]. Moreover, the loss of the *TP53* locus is a common finding in gastric neoplasias of individuals from Northern Brazil [12].

The aim of the present study was to determine whether *hTERT*, *MYC*, and *TP53* mRNA expression, as well as their protein products, are deregulated in gastric preoplastic lesions from cancer-free individuals of Northern Brazil. The number of *TP53* gene copies was also evaluated in gastric diseases.

Results

hTERT, MYC, and p53 immunostaining was only detected in intestinal metaplasia samples (Figure 1, Table 1). The frequency of hTERT ($\chi^2 = 19.243$, df = 2, p < 0.001, by Pearson Chi-square, V = 0.592), MYC ($\chi^2 = 19.243$, df = 2, p < 0.001, V = 0.592), and p53 ($\chi^2 = 13.844$, df = 2, p = 0.001, V = 0.502) immunoreactivity differed among groups (Table 1). Using the Bonferroni correction, a series of Fisher exact tests demonstrated that the frequency of hTERT (p = 0.001, OR = 1.9), MYC (p = 0.001, OR = 1.9), and p53 (p = 0.01, OR = 1.58) immunoreactivity was higher in intestinal metaplasia than in superficial gastritis. Intestinal metaplasia samples also presented a higher frequency of hTERT (p = 0.001,

OR = 1.8), MYC (p = 0.001, OR = 1.8), and p53 (p = 0.008, OR = 1.5) immunoreactivity compared to atrophic gastritis specimens. hTERT was strongly associated with MYC ($\chi^2 = 40.086$, df = 1, p < 0.001, V = 0.854, OR = 0.024) and p53 ($\chi^2 = 39.566$, df = 1, p < 0.001, V = 0.848, OR = 0.041) immunoreactivity. MYC and p53 immunoreactivity was also strongly associated ($\chi^2 = 25.638$, df = 1, p < 0.001, V = 0.683, OR = 0.073). Five of 18 (27.8%) intestinal metaplasia samples presented immunoreactivity for the three studied proteins.

We observed a significant difference in *MYC* ($F = _{2,52} = 41.172$, p < 0.001, by ANOVA test, $\eta^2 = 0.613$) mRNA expression among the studied groups (Table 1). Tukey post-hoc analyses revealed that *MYC* mRNA expression was higher in intestinal metaplasia than superficial (p < 0.001) and atrophic (p < 0.001) gastritis. A 1.5-fold increase in *MYC* expression was detected in 83.3% of intestinal metaplasia samples. The *MYC* mRNA expression tended to be higher in samples with H. pylori than samples without this pathogen ($T_{53} = -1.934$, p = 0.058, by Student test, r = 0.257). *MYC* and *TP53* mRNA expression were not correlated (p = 0.334, r = 0.133). *hTERT* was weakly correlated to *MYC* and *TP53* mRNA expression (p = 0.047, r = 0.267; p = 0.028, r = 0.296, respectively).

Higher *hTERT* and *MYC* mRNA expression was associated with MYC immunoreactivity ($T_{53} = -3.218$, p = 0.002, by Student test, r = 0.398; $T_{53} = --7.429$, p < 0.001, r = 0.701, respectively). Higher *hTERT, MYC,* and *TP53* mRNA expression was associated with hTERT ($T_{53} = -3.658$, p = 0.001, r = 0.442; $T_{53} = -5.88$, p < 0.001, r = 0.621; $T_{53} = -2.316$, p = 0.024; r = 0.298, respectively) and p53 ($T_{53} = -2.495$, p = 0.016, r = 0.319; $T_{53} = -4.64$, p < 0.001, r = 0.530; $T_{53} = -2.674$, p = 0.010; r = 0.339, respectively) immunoreactivity.

One sample of superficial gastritis presented 3 copies of *TP53* and this case was excluded from the CNV statistical analyses. Loss of *TP53* copies was observed only in the group of intestinal metaplasia samples (Table 1). The frequency of *TP53* loss was significantly higher in intestinal metaplasia samples compared to gastritis specimens ($\chi^2 = 6.353$, df = 1, p = 0.033, by Fisher exact test, V = 0.343, OR = 2.4). The loss of *TP53* copies was associated with hTERT ($\chi^2 = 18.265$, df = 1, p = 0.002, V = 0.582; OR = 1.6) and p53 ($\chi^2 = 9.926$, df = 1, p = 0.03, V = 0.429, OR = 1.47) immunoreactivity. However, this analysis should be considered with care since only 3 cases presented loss of *TP53* copies.

Discussion

Telomerase activation is thought to be essential for the stabilization of telomere length, through which immortalization and oncogenesis are achieved, but little is known about the regulation of the hTERT subunit in

Figure 1 Immunostaining of hTERT, MYC and p53. (A) Absence of hTERT staining in atrophic gastritis (100×); (**B**) hTERT immunoreactivity in intestinal metaplasia (400×); (**C**) Atrophic gastritis without MYC immunoreactivity (100×); (**D**) MYC immunopositivity in intestinal metaplasia (400×); (**E**) Absence of p53 immunoreactivity in atrophic gastritis (100×); (**F**) negative control (400×).

human precancerous gastric lesions. In the present study, we observed that hTERT, MYC, and p53 immunoreactivity was only present in intestinal metaplasia samples. In addition, we detected a strong association among these three proteins and 27.8% of intestinal metaplasia samples presented immunostaining of the three studied proteins. MYC is a transcriptional activator and p53 is a repressor of *hTERT* expression [6]. Some studies favored the view that MYC drove initial proliferation and subsequent differentiation, concomitant with the activation of the p53 G2 checkpoint and also demonstrated that inactivation of the p53-Rb pathway is required for immortalization through overepression of MYC [13,14]. Thus, some cases of intestinal metaplasia may carry short telomeres and due to this telomere dysfunction, MYC stimulates hTERT expression. However, in the absence of genome checkpoint functions (i.e. p53

mutations or *TP53* deletion), this process will favor the proliferation of immortalized cells carrying genetic and epigenetic alterations and tumor initiation.

It is important to note that, although intestinal metaplasia precedes intestinal-type gastric cancer, only few individuals with this preneoplastic lesion will develop gastric tumors. Further investigation are necessary to evaluate the role of hTERT, MYC, and p53 proteins – alterations common described in gastric neoplasia – in the disease progression, ideally with biopsies of intestinal metaplasia and tumor from the same patients. These biomarkers may be useful for the assessment of gastric cancer risk if validated in a larger clinical study sets.

Some studies demonstrated that hTERT expression increases with the sequential steps of intestinal-type gastric carcinogenesis [15-19], suggesting that hTERT deregulation represents an important step in the

Table 1 Clinicopathological characteristics, *MYC*, *hTERT* and *TP53* expression, and *TP53* copies in gastric samples

	Superficial gastritis	Atrophic gastritis	Intestinal metaplasia
Gender			
Male [N (%)]	12 (63.2)	11 (61.1)	12 (66.7)
Female [N (%)]	7(36.8)	7 (38.9)	6 (33.3)
Alcohol consumption			
Negative [N (%)]	10 (52.6)	10 (55.6)	12 (66.7)
Positive [N (%)]	9 (47.4)	8 (44.4)	6 (33.3)
Cigarette smoking			
Negative [N (%)]	10 (52.6)	12 (66.7)	9 (50)
Positive* [N (%)]	9 (47.4)	6 (33.3)	9 (50)
H. pylori infection			
Negative [N (%)]	7 (36.8)	5 (27.8)	1 (5.6)
Positive [N (%)]	12 (63.2)	13 (72.2)	17 (94.4)
***hTERT* mRNA expression**			
RQ (Mean ± SD)	1.092 ± 0.61	0.821 ± 0.47	1.184 ± 0.55
***MYC* mRNA expression**			
RQ (Mean ± SD)	0.852 ± 0.51**	0.873 ± 0.28**	1.901 ± 0.49
***TP53* mRNA expression**			
RQ (Mean ± SD)	0.997 ± 0.59	0.847 ± 0.79	1.021 ± 0.61
hTERT immunoreactivity			
Negative [N (%)]	19 (100)	18 (100)	10 (55.6)
Positive [N (%)]	0 (0)**	0 (0)**	8 (44.4)
MYC immunoreactivity			
Negative [N (%)]	19 (100)	18 (100)	10 (55.6)
Positive [N (%)]	0 (0)**	0 (0)**	8 (44.4)
p53immunoreactivity			
Negative [N (%)]	19 (100)	18 (100)	12 (66.7)
Positive [N (%)]	0 (0)**	0 (0)**	6 (33.3)
***TP53* copies**			
2 copies [N (%)]	18 (100)	18 (100)	15 (83.3)
1 copy [N (%)]	0 (0)	0 (0)	3 (16.7)***

RQ: relative quantification.
*Patients smoking one or more cigarettes per day (range 1–20).
**Significantly different from intestinal metaplasia group.
***Gastritis was significantly different from intestinal metaplasia group.

carcinogenesis progress. We also previously demonstrated that 80% of gastric tumors and no non-neoplastic gastric mucosa of individuals from Northern Brazil presented hTERT immunoreactivity, suggesting that hTERT may have an impact on the anti-telomerase strategy for cancer therapy [20].

The detection of MYC immunoreactivity in intestinal metaplasia of individuals from three Northern Brazil populations corroborates previous studies of our group that demonstrated the presence of MYC protein overexpression only in intestinal metaplasia and neoplastic tissue from all patients with intestinal type gastric cancer, which is preceded by preneoplastic lesions [21-23], as well as in intestinal metaplasia of non-human primates treated with N-methyl-nitrosourea (MNU) [24]. On the other hand, MYC immunoreactivity was described in gastritis samples, as well as intestinal metaplasia, in Asian populations [15,25-27].

Here, MYC immunoreactivity was strongly associated with increased mRNA expression. To our knowledge, this is the first study to sensitively quantify *MYC* mRNA expression in precancerous gastric lesions. The increased MYC expression in intestinal metaplasia supports a previous study of our group in non-human primates, in

which we demonstrated a continuous increase of *MYC* mRNA expression during the sequential steps of gastric carcinogenesis in MNU-treated animals [24]. In these animals, the mRNA expression increased about 3-fold in intestinal metaplasia compared to normal gastric mucosa. In addition, we previously reported that a significant increase of *MYC* copy number was seen with the evolution of carcinogenesis process in humans and non-human primates [21,24], which may contribute to the increased mRNA expression and protein immunoreactivity. In addition, *MYC* amplification or trisomy of chromosome 8, where *MYC* is located, was detected in all human gastric cancer of individuals from Northern Brazil [21-23,28-31], as well as in gastric cancer cell lines established from the tumors of Brazilian patients [32-35], supporting that *MYC* has a key role in gastric carcinogenesis.

Previously we also reported the presence of p53 immunoreactivity in all intestinal-type gastric cancer of individuals from Northern Brazil [12]. The p53 immunoreactivity usually depends on the accumulation of mutated p53 proteins in the cell, which leads to a longer half-life [36]. Some studies have demonstrated *TP53* mutations in gastritis [37] and intestinal metaplasia [38,39] as well as gastric cancer, which corroborates the observation of p53 immunoreactivity in intestinal metaplasia samples of the studied population. The presence of p53 immunostaining only in intestinal metaplasia corroborates previous studies of literature [15,40]. However, Targa et al. [41] reported p53 overexpression in 5/19 (26.3%) of chronic gastritis, 1/8 (12.5%) of atrophic gastritis and 2/11 (18.2%) of intestinal metaplasia of individuals from Southeastern Brazil.

To our knowledge, few studies evaluated the number of copies of *TP53* in pre-neoplastic gastric lesions. Loss of heterozygosity at the *TP53* locus is one of the most common mechanisms involved in this gene pathway deregulation. Loss of *TP53* is a frequent finding in gastric cancer [42]. Previously, our group demonstrated that the loss of *TP53* copies and aneusomy of chromosome 17, where this gene is located, was present in all gastric cancer samples of individuals from Pará State, Northern Brazil [12], and also in all gastric cancer cell lines established from neoplasias in this population [33,43]. Here, we observed *TP53* deletion in 16.7% of intestinal metaplasia in individuals from Northern Brazil by qPCR. In a Southeastern Brazilian population, it was described that 3/5 (60%) of intestinal metaplasia samples presented loss of *TP53* by fluorescence in situ hybridization (FISH) assay [36]. Williams et al. [42] also reported that the deletion of *TP53* was a common event in premalignant stages of gastric carcinogenesis by FISH analyses. These authors demonstrated that this alteration was about 3-fold increased in intestinal metaplasia (N = 4) compared

to normal gastric tissue. Since *TP53* is a critical tumor suppressor gene in the carcinogenesis process, the loss of this gene copy and its protein immunoreactivity in the intestinal metaplasia stage may contribute for tumor initiation.

Conclusions

In conclusion, hTERT, MYC, and TP53 are deregulated in intestinal metaplasia of individuals from Northern Brazil and these alterations may facilitate tumor initiation.

Methods
Clinical samples

Samples were obtained from cancer-free patients including 19 with superficial gastritis, 18 with atrophic gastritis, and 18 patients with intestinal metaplasia by endoscopy. From each patient, normal tissue sample were also collected. Samples were collected at endoscopy services in Pará, Maranhão and Ceará States in Northern Brazil. Informed consent with approval of the ethics committee of the Federal University of Pará was obtained. Tissue specimens were immediately frozen in liquid nitrogen and kept at –80°C until RNA and DNA extraction. All studied samples were negative for Epstein-Barr infection by in situ hybridization method [44]. The presence of *Helicobacter pylori*, a class I carcinogen, in gastric samples was detected by the PCR assay for the urease gene [45]. Table 1 shows the clinicopathological characteristics of patients.

Immunohistochemistry

Immunohistochemical analyses were performed on formalin-fixed, paraffin-embedded sections. Immunohistochemical staining was performed on the paraffin sections according to Calcagno et al. [22] with primary mouse monoclonal antibody against hTERT (dilution 1:50; clone 44 F12, Novocastra Laboratories Ltd, UK), MYC (dilution 1:150; sc-40, Santa Cruz Biotechnology, USA and Zymed®, USA), or p53 (dilution 1:50; Dakocytomation, USA). A universal peroxidase-conjugated secondary antibody kit (LSAB System, DakoCytomation, USA) was used for the detection system, and diaminobenzidine (DAB) was the applied chromogen. Positive protein expression was defined as clear nuclear imunostaining in more than 10% of the cells.

mRNA expression

Total RNA was extracted with Tri-reagent (Applied Biosystems, USA) following the manufacturer's instructions. RNA concentration and quality were determined using the NanoDrop spectrophotometer (Kisker, Germany) and 1% agarose gels. Complementary DNA was synthesized using High-Capacity cDNA Archive (Applied Biosystems, Poland).

hTERT, MYC, and *TP53* mRNA expression was evaluated by quantitative reverse transcription PCR (qRT-PCR) with primers and TaqMan probes purchased as Assays-on-demand Products for Gene Expression (Applied Biosystems, USA). *GAPDH* gene was selected as an internal control for RNA input and reverse transcription efficiency. All real-time qRT-PCR reactions were performed in triplicate for all target genes (*hTERT*: Hs00972656_m1; *MYC*: Hs00153408_m1; *TP53*: Hs01034249_m1) and the internal control (*GAPDH*: NM_002046.3).

Relative quantification (RQ) of the gene expression was calculated according to Livak and Schmittgen [46]. In the present study, the corresponding normal tissue sample was designated as a calibrator for superficial gastritis, atrophic gastritis, or intestinal metaplasia sample from each patient.

TP53 copy number variation (CNV)

Quantitative TaqMan CNV assays (Applied Biosystems, USA) were used as a confirmation to FISH analysis. Duplex quantitative PCR (qPCR) was performed using the FAM/MGB-labeled TaqMan probe for *TP53* gene (Hs06423639_cn) and VIC/TAMRA-labeled TaqMan CNV *RNAse P* (#4403326) for the internal control. qPCR reactions were performed in quadruplicate with genomic DNA (gDNA) according to the manufacturer's protocol and cycling conditions in 7500 Fast Real-Time PCR (Applied Biosystems, USA). Relative quantification analysis was done to estimate the copy number for each sample by using the Copy Caller Software V1.0 (Applied Biosystems, USA). A known human gDNA (Promega, USA) was used for calibration.

Data analysis

Chi-square test was performed to analyze hTERT, MYC, and p53 immunostaining, as well as *TP53* CNV data. To take into account the multiple testing, Bonferroni corrections were applied to adjust the Chi-squared p value when necessary. Shapiro-Wilk normality test was used to evaluate the normal distribution of mRNA expression data and to determine subsequent use of appropriate tests for statistical comparison. Data that were not normally distributed were transformed (z-score transformation) for the analysis of variance in gene expression such that they followed a normal distribution. Analyses of variance in mRNA expression were performed by one-way ANOVA followed by Tukey (homogeneity of variances according to Levene test) post-hoc test. Chi-square and Student's T test were used to assess the relationship between gene expression, protein immunoreactivity, and CNV results and clinicopathological factors.

The effect size for Chi-square was based on Cramer's phi (V) and the effect size correlation directly from the Student T test as "r" (Pearson correlation coefficient), in which a value between 0.1-0.29 was determined as a small effect size; 0.3-0.49 as a medium effect size; and 0.50 or above as a large effect size. The effect size for ANOVA analyses was based on Eta Squared (η^2), in which values 0.15 and below were determined as a small effect size; 0.16-0.40 as a medium effect size; and above 0.40 as a large effect size.

The correlation between *hTERT, MYC,* and *TP53* mRNA expression was analyzed by the Pearson test, in which a value below 0.30 was determined as a weak correlation; 0.30-0.70 as a medium correlation; and above 0.70 as a strong correlation.

In all analyses, the confidence interval was 95% and *p* values less than 0.05 were considered significant.

Authors' contributions
MFL, TCRS, PPA, MACS and RRB conceived and designed the experiments. TCRS, MFL, DQC, RCM and MQN performed the experiments. TCRS, MFL, DQC, CRT, ASK, NPCS, MACS, and RRB analyzed the data. NPCS, SHBR and PPA contributed reagents/materials/analysis tools. MFL, TCRS, MACS and RRB wrote the paper. All authors read and approved the final manuscript.

Author details
[1]Laboratório de Citogenética Humana, Instituto de Ciências Biológicas, Universidade Federal do Pará, CEP: 66073-000, Belém, PA, Brazil. [2]Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, Rua Botucatu 740, CEP 04023-900, São Paulo, SP, Brazil. [3]Unidade de Alta Complexidade em Oncologia, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, CEP: 60673-000, Belém, PA, Brazil. [4]Laboratório de Genética Molecular, Departamento de Patologia e Medicina Forense, Escola de Medicina, Universidade Federal do Ceará, CEP: 60020-181, Fortaleza, CE, Brazil.

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: **Global cancer statistics.** *CA Cancer J Clin* 2011, **61**(2):69–90.
2. Instituto Nacional de Câncer - INCA: *Estimate/2010 - Incidence of Cancer in Brazil.* Rio de Janeiro: Instituto Nacional de Câncer/Ministério da Saúde; 2009:98.
3. Correa P: **Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention.** *Cancer Res* 1992, **52**(24):6735–6740.
4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: **Specific association of human telomerase activity with immortal cells and cancer.** *Science* 1994, **266**(5193):2011–2015.
5. Artandi SE, DePinho RA: **Mice without telomerase: what can they teach us about human cancer?** *Nat Med* 2000, **6**(8):852–855.

6. Kyo S, Takakura M, Fujiwara T, Inoue M: **Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.** *Cancer Sci* 2008, **99**(8):1528–1538.

7. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR: **MYC and gastric adenocarcinoma carcinogenesis.** *World J Gastroenterol* 2008, **14**(39):5962–5968.

8. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B: **Genomic targets of the human c-Myc protein.** *Genes Dev* 2003, **17**(9):1115–1129.

9. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F: **The c-Myc target gene network.** *Semin Cancer Biol* 2006, **16**(4):253–264.

10. Szymanska K, Hainaut P: **TP53 and mutations in human cancer.** *Acta Biochim Pol* 2003, **50**(1):231–238.

11. Vousden KH, Ryan KM: **p53 and metabolism.** *Nat Rev Cancer* 2009, **9**(10):691–700.

12. Khayat AS, Guimaraes AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpcao PP, Demachki S, *et al*: **Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.** *BMC Gastroenterol* 2009, **9**:55.

13. Pelengaris S, Rudolph B, Littlewood T: **Action of Myc in vivo - proliferation and apoptosis.** *Curr Opin Genet Dev* 2000, **10**(1):100–105.

14. Dazard JE, Piette J, Basset-Seguin N, Blanchard JM, Gandarillas A: **Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size.** *Oncogene* 2000, **19**(33):3693–3705.

15. Lan J, Xiong YY, Lin YX, Wang BC, Gong LL, Xu HS, Guo GS: **Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation.** *World J Gastroenterol* 2003, **9**(1):54–58.

16. Wang W, Luo HS, Yu BP: **Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions.** *World J Gastroenterol* 2004, **10**(2):177–181.

17. Cassaro M, Rugge M, Tieppo C, Giacomelli L, Velo D, Nitti D, Farinati F: **Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype.** *J Clin Pathol* 2007, **60**(6):615–621.

18. Gulmann C, Lantuejoul S, Grace A, Leader M, Patchett S, Kay E: **Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT.** *Dig Liver Dis* 2005, **37**(6):439–445.

19. Jong HS, Park YI, Kim S, Sohn JH, Kang SH, Song SH, Bang YJ, Kim NK: **Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis.** *Cancer* 1999, **86**(4):559–565.

20. Gigek CO, Leal MF, Silva PN, Lisboa LC, Lima EM, Calcagno DQ, Assumpcao PP, Burbano RR, Smith MA: **hTERT methylation and expression in gastric cancer.** *Biomarkers* 2009, **14**(8):630–636.

21. Calcagno DQ, Leal MF, Demachki S, Araujo MT, Freitas FW: **SD Oliveira e, Assumpcao PP, Ishak G, de Arruda Cardoso Smith M, Burbano RR: MYC in gastric carcinoma and intestinal metaplasia of young adults.** *Cancer Genet Cytogenet* 2010, **202**(1):63–66.

22. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpcao PP, Faria MH, Rabenhorst SH, Ferreira MV, *et al*: **Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.** *World J Gastroenterol* 2006, **12**(38):6207–6211.

23. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimaraes AC, Calcagno DQ, Khayat AS, Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR: **Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma.** *Cancer Genet Cytogenet* 2008, **181**(1):31–35.

24. da Costa Jde F, Leal MF, Silva TC, Andrade Junior EF, Rezende AP, Muniz JA, Lacreta Junior AC, Assumpcao PP, Calcagno DQ, Demachki S, *et al*: **Experimental gastric carcinogenesis in Cebus apella nonhuman primates.** *PLoS One* 2011, **6**(7):e21988.

25. Han JC, Zhang KL, Chen XY, Jiang HF, Kong QY, Sun Y, Wu ML, Huang L, Li H, Liu J: **Expression of seven gastric cancer-associated genes and its relevance for Wnt, NF-kappaB and Stat3 signaling.** *APMIS* 2007, **115**(12):1331–1343.

26. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J: **Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions**

and adenocarcinoma: association with Helicobactor pylori cagA (+) infection. *World J Gastroenterol* 2004, **10**(4):491–496.

27. Zhang GX, Gu YH, Zhao ZQ, Xu SF, Zhang HJ, Wang HD, Hao B: **Coordinate increase of telomerase activity and c-Myc expression in Helicobacter pylori-associated gastric diseases.** *World J Gastroenterol* 2004, **10**(12):1759–1762.

28. Assumpcao PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimaraes AC, Calcagno DQ, Khayat AS, Demachki S, Smith MA, *et al*: **Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma.** *Cancer Genet Cytogenet* 2006, **169**(1):45–49.

29. Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: **C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.** *Anticancer Res* 2006, **26**(4B):2909–2914.

30. Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A, Burbano RR: **Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.** *Anticancer Res* 2005, **25**(6B):4069–4074.

31. Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpcao PP: **De Arruda Cardoso Smith M, Burbano RR: MYC insertions in diffuse-type gastric adenocarcinoma.** *Anticancer Res* 2009, **29**(7):2479–2483.

32. Leal MF, Calcagno DQ: **da Borges Costa JF, Silva TC, Khayat AS, Chen ES, Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR: MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors.** *J Biomed Biotechnol* 2011, **2011**:631268.

33. Leal MF: **Nascimento JL Martins do, da Silva CE, Vita Lamarao MF, Calcagno DQ, Khayat AS, Assumpcao PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR: Establishment and conventional cytogenetic characterization of three gastric cancer cell lines.** *Cancer Genet Cytogenet* 2009, **195**(1):85–91.

34. Ribeiro HF, Alcantara DF, Matos LA, Sousa JM, Leal MF, Smith MA, Burbano RR, Bahia MO: **Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line.** *Braz J Med Biol Res* 2010, **43**(8):717–721.

35. Costa Guimaraes A, Goncalves Quintana L, Ferreira Leal M, Satomi Takeno S, Pimentel Assumpcao P, Moura Lima E, Salim Khayat A, Suchi Chen E, de Arruda Cardoso Smith M, Rodriguez Burbano R: **Aneuploidy of chromosome 8 detected by fluorescence in situ hybridisation in ACP01 cell line gastric adenocarcinoma.** *Clin Exp Med* 2006, **6**(3):129–133.

36. Cesar AC, Borim AA, Caetano A, Cury PM, Silva AE: **Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer.** *Cancer Genet Cytogenet* 2004, **153**(2):127–132.

37. Morgan C, Jenkins GJ, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM: **Detection of p53 mutations in precancerous gastric tissue.** *Br J Cancer* 2003, **89**(7):1314–1319.

38. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: **p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer.** *Int J Cancer* 1993, **54**(5):759–764.

39. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: **p53 alteration in gastric precancerous lesions.** *Am J Pathol* 1994, **144**(3):511–517.

40. Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E: **Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions.** *Dig Dis Sci* 2002, **47**(1):107–113.

41. Targa AC, Cesar AC, Cury PM, Silva AE: **Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy.** *Genet Mol Res* 2007, **6**(3):554–565.

42. Williams L, Jenkins GJ, Doak SH, Fowler P, Parry EM, Brown TH, Griffiths AP, Williams JG, Parry JM: **Fluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pylori.** *Br J Cancer* 2005, **92**(9):1759–1766.

43. Leal MF, Calcagno DQ: **da Costa JF Borges, Silva TC, Khayat AS, Chen ES, Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR: MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors.** *J Biomed Biotechnol* 2010, **2011**:631268.

44. Bacchi MM, Bacchi CE, Alvarenga M, Miranda R, Chen YY, Weiss LM: **Burkitt's lymphoma in Brazil: strong association with Epstein-Barr virus.** *Mod Pathol* 1996, **9**(1):63–67.

45. Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S: **Sensitive detection of Helicobacter pylori by using polymerase chain reaction.** *J Clin Microbiol* 1992, **30**(1):192–200.

46. Arocho A, Chen B, Ladanyi M, Pan Q: **Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts.** *Diagn Mol Pathol* 2006, **15**(1):56–61.